Compare FHTX & BBCQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHTX | BBCQ |
|---|---|---|
| Founded | 2015 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.2M | 381.0M |
| IPO Year | 2020 | N/A |
| Metric | FHTX | BBCQ |
|---|---|---|
| Price | $5.78 | $10.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $11.71 | N/A |
| AVG Volume (30 Days) | 111.3K | ★ 172.7K |
| Earning Date | 04-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.48 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,602,000.00 | N/A |
| Revenue This Year | $40.87 | N/A |
| Revenue Next Year | $11.27 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.94 | $9.92 |
| 52 Week High | $6.95 | $10.15 |
| Indicator | FHTX | BBCQ |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 62.63 |
| Support Level | $4.44 | $9.94 |
| Resistance Level | $5.85 | N/A |
| Average True Range (ATR) | 0.34 | 0.02 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 73.76 | 60.87 |
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Bleichroeder Acquisition Corp II is a blank check company incorporated. The company was incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses that the company has not yet identified.